Literature DB >> 32307765

MicroRNA-93 targets WASF3 and functions as a metastasis suppressor in breast cancer.

Naoki Shibuya1,2, Yoshihiro Kakeji2, Yohei Shimono1,3.   

Abstract

Cancer cells with cancer stem cell (CSC) properties initiate both primary tumor formation and metastases at distant sites. Acquisition of CSC properties is highly associated with epigenetic alterations, including those mediated by microRNAs (miRNAs). We have previously established the breast cancer patient-derived tumor xenograft (PDX) mouse model in which CSC marker CD44+ cancer cells formed spontaneous microscopic metastases in the liver. In this PDX mouse, we found that the expression levels of 3 miRNAs (miR-25, miR-93, and miR-106b) in the miR-106b-25 cluster were much lower in the CD44+ human cancer cells metastasized to the liver than those at the primary site. Constitutive overexpression of miR-93 suppressed invasive ability and 3D-organoid formation capacity of breast cancer cells in vitro and significantly suppressed their metastatic ability to the liver in vivo. Wiskott-Aldrich syndrome protein family member 3 (WASF3), a regulator of both cytoskeleton remodeling and CSC properties, was identified as a functional target of miR-93: overexpression of miR-93 reduced the protein level of WASF3 in breast cancer cells and WASF3 rescued the miR-93-mediated suppression of breast cancer cell invasion. These findings suggest that miR-93 functions as a metastasis suppressor by suppressing both invasion ability and CSC properties in breast cancers.
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  WASF3; breast cancer; cancer stem cell; metastasis; miR-93

Year:  2020        PMID: 32307765     DOI: 10.1111/cas.14423

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  7 in total

1.  Circular RNA OMA1 regulates the progression of breast cancer via modulation of the miR‑1276/SIRT4 axis.

Authors:  Lingli Xu; Ke Xu; Lijun Xiang; Jiamei Yan
Journal:  Mol Med Rep       Date:  2021-08-20       Impact factor: 2.952

Review 2.  Circulating miRNAs in Breast Cancer Diagnosis and Prognosis.

Authors:  Barbara Cardinali; Roberta Tasso; Patrizia Piccioli; Maria Chiara Ciferri; Rodolfo Quarto; Lucia Del Mastro
Journal:  Cancers (Basel)       Date:  2022-05-07       Impact factor: 6.575

Review 3.  Targeting WASF3 Signaling in Metastatic Cancer.

Authors:  Reid Loveless; Yong Teng
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

4.  microRNA-128-3p inhibits CD4+ regulatory T cells enrichment by targeting interleukin 16 in gastric cancer.

Authors:  Weidan Fang; Chao Shi; Yiting Wang; Jianping Song; Ling Zhang
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

5.  LncRNA HCP5 enhances the proliferation and migration of cervical cancer via miR-216a-5p/CDC42 axis.

Authors:  Xiaomin Li; Bingxin Chen; Anni Huang; Ci Ren; Liming Wang; Tong Zhu; Jinfeng Xiong; Wencheng Ding; Hui Wang
Journal:  J Cancer       Date:  2022-03-21       Impact factor: 4.207

6.  MicroRNA-93-5p participates in type 2 diabetic retinopathy through targeting Sirt1.

Authors:  Hui Wang; Xian Su; Qian-Qian Zhang; Ying-Ying Zhang; Zhan-Ya Chu; Jin-Ling Zhang; Qian Ren
Journal:  Int Ophthalmol       Date:  2021-07-27       Impact factor: 2.031

7.  Upregulation of S100A10 in metastasized breast cancer stem cells.

Authors:  Hisano Yanagi; Takashi Watanabe; Tatsunori Nishimura; Takanori Hayashi; Seishi Kono; Hitomi Tsuchida; Munetsugu Hirata; Yuko Kijima; Shintaro Takao; Seiji Okada; Motoshi Suzuki; Kazuyoshi Imaizumi; Kenji Kawada; Hironobu Minami; Noriko Gotoh; Yohei Shimono
Journal:  Cancer Sci       Date:  2020-10-11       Impact factor: 6.716

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.